Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.08, read 2026-11-05
Ethical passes the values gate
Price76.28 USD
Fair value60.09
Ethical score70.0/100
Value readOvervaluedas of 5 Nov 2026
Our investment reviews on this name
2026-10-11Read Accumulation69.52+9.7% to today ✓Markdown gives way to Accumulation
2026-09-24Read Markdown69.06+10.5% to today Markup gives way to Markdown after a 6% rise in 12 weeks
2026-07-02Read Markup64.98+17.4% to today ✓First review on file: Markup
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Ashland Inc. holds its Accumulation at $76.28. Consolidating, no directional conviction, held for 46 days.
As held on the ledger · 2026-11-05
Phase
Accumulation
Quantitative state
Consolidating, no directional conviction, held for 46 days
Price at the screen
$76.28
Valuation
49.00 trailing · 16.07 forward price to earnings
Values screen
PASS· score 70.0
Beta
0.36
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
32.31%
Below 33%
Interest-bearing debt is just 32.3% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
9.91%
Below 49%
Money owed to the company is 9.9% of assets, under the 49% limit.
Pass
Revenue purity
0.27%
Below 5%
Only 0.3% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Clears, in Plain English
Ashland clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 32%, inside the ~33% line, and almost none of its income is interest, so it passes.
Read as at 2026-11-05. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when ASH's ethical verdict changes
Today ASH passes the screen. If new figures move it to a fail, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads Overvalued vs our fair value, as of 5 Nov 2026: it trades above our $60.09 fair value estimate, 7.30% revenue growth.
Fair value range in USD, drawn from the 2026-11-05 screen. The gold marker is the market price at the same screen. The price runs 26.9% above the base estimate.
Where our models see it going: fair-value estimate $60.09, with a range of $60.09 to $69.10, dated to the 2026-11-05 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Chemicals maker priced for recovery that numbers reject
Picture a supplier of additives whose products end up in medicines and creams yet whose own books show deep red ink. Ashland trades well above our calculated worth with a negative margin of safety, and the bare facts give no reason to step in. Revenue barely moves while profits and returns sit deep in the red, so the current price simply does not match the business on show.
The forward multiple sits at sixteen times but offers no bargain once the cyclical trap is considered. Peak earnings often arrive just before the next downturn in specialty chemicals, and here earnings have already collapsed. Analyst targets sit higher yet rest on hopes rather than the delivered results of one percent growth and sharply negative returns on equity.
Currency swings, raw-material costs and demand drops in construction and consumer goods all sit ready to widen the gap between price and value. The ethical screen clears, yet that alone cannot rescue weak fundamentals. Analysis, not advice.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
ASH trades on the NYSE. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-03Accumulation$74.19-0.7%Entry 19
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.7% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 15% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 25%. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (11 analysts) rates it buy, with a mean price target of $64. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-02Accumulation$74.68+0.0%Entry 18
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 15% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 25%. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (11 analysts) rates it buy, with a mean price target of $64. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-01Accumulation$74.68+0.0%Entry 17
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 15% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 25%. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (11 analysts) rates it buy, with a mean price target of $64. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-31Accumulation$74.68+0.4%Entry 16
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 0.4% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 15% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 25%. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (11 analysts) rates it buy, with a mean price target of $64. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-30Accumulation$74.38+2.4%Entry 15
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 2.4% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 15% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 25%. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (11 analysts) rates it buy, with a mean price target of $64. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-29Accumulation$72.67+0.7%Entry 14
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 0.7% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 15% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 25%. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (11 analysts) rates it buy, with a mean price target of $64. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-28Accumulation$72.14+0.0%Entry 13
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 15% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 25%. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (11 analysts) rates it buy, with a mean price target of $64. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-27Accumulation$72.14+0.0%Entry 12
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 15% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 25%. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (11 analysts) rates it buy, with a mean price target of $64. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-25Accumulation$72.14+0.8%Entry 11
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 0.8% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 13% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 25%. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (11 analysts) rates it buy, with a mean price target of $64.
2026-10-18Accumulation$71.59+3.0%Entry 10
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 3.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are up 25%. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (11 analysts) rates it buy, with a mean price target of $64.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
